| Literature DB >> 30603015 |
Isaac Adembesa1, Vitalis Mung'ayi1, Zulfiqarali Premji2, Dorothy Kamya1.
Abstract
BACKGROUND: There is increasing evidence that the incidence of postoperative residual paresis after using neuromuscular blockers ranges from 24 to 50% in post anaesthesia care unit (PACU) and is associated with postoperative complications such as critical respiratory events as evidenced by hypoxia, hypoventilation and upper airway obstruction. Quantitative neuromuscular monitoring (such as the assessment of Train of four (TOF) ratio) and reversal of neuromuscular blockers has been shown to reduce postoperative residual paresis. There are very few outcome studies on effect of residual paresis in PACU. There is a paucity of published randomized controlled trials investigating whether using a TOF ratio ≥0.9 before endotracheal extubation compared to clinical assessment of return of neuromuscular function reduces the incidence of critical respiratory events in PACU.Entities:
Keywords: Nairobi; Randomized control trial; elective surgery; neuromuscular function
Mesh:
Year: 2018 PMID: 30603015 PMCID: PMC6306997 DOI: 10.4314/ahs.v18i3.40
Source DB: PubMed Journal: Afr Health Sci ISSN: 1680-6905 Impact factor: 0.927
Figure 1Flow diagram of patient distribution
shows patient characteristics
| Clinical assessment | TOF group | P-values | |
| Sex, M:F | 38(45%),46(55%) | 36(43%),48(57%) | 0.756 |
| Age in yrs | 37.5(29–47) | 37(30–44) | 0.8192 |
| BMI | 25.5(22.4–27.3) | 24.65(22.45–27.2) | 0.9380 |
| ASA status | |||
| I | 57(68%) | 61(73%) | 0.500 |
| II | 27(32%) | 23(27%) | 0.500 |
| Smoking, No/Yes | 80(95%), 4(5%) | 80(95%), 4(5%) | 1.000 |
| 2(2%) | 3(4%) | 0.650 | |
| ENT | 23(27%) | 23(27%) | 1.000 |
| General | 21(25%) | 30(36%) | 0.131 |
| Gynecologic | 1(1%) | 5(6%) | 0.096 |
| Maxillofacial | 1(1%) | 0(0%) | 0.316 |
| Ophthalmologic | 19(23%) | 15(18%) | 0.442 |
| Orthopedics | 17(21%) | 7(8%) | 0.027 |
| Urologic | 0(0%) | 1(1%) | 0.316 |
| Plastic |
Median and 25th–75th percentiles are given for age and BMI. Otherwise, numbers of patients (and % of patients) are given.
P-values for patients' data with median were calculated using Wilcoxon rank sum test while those with proportions were calculated using Pearson Chi-square test.
BMI-Body mass index, ASA- American Society of Anaesthesiology, ENT-Ear, Nose and Throat
shows Perioperative variables
| Clinical | TOF | 95%Confidence | P-values | |
| Anaesthetic duration (mins) | 130±71 | 134±70 | −25.7 to 17.3 | 0.6994 |
| Surgical duration (mins) | 114±66 | 119±67 | −25.8 to 15.0 | 0.6018 |
| Duration since last muscle relaxant (mins) | 53±16 | 53±15 | −4.9 to 4.8 | 0.9806 |
shows SPO2 values on arrival in post anaesthesia care unit
| Clinical assessment | TOF group | P-values | |
| No. with SPO2 >94% | 59(70%) | 72(85%) | 0.016 |
| No. with SPO2 90–93% | 9(11%) | 4(5%) | 0.149 |
| No. with SPO2 <90% | 16(19%) | 8(10%) | 0.078 |
shows SPO2 values for first 30 minutes in the post anaesthesia care unit
| Clinical assessment | TOF group | P-values | |
| No. with SPO2 >94% | 68(81%) | 79(94%) | 0.010 |
| No. with SPO2 90–93% | 10(12%) | 1(1%) | 0.005 |
| No. with SPO2 <90% | 6(7%) | 4(5%) | 0.373 |
shows airway variables in the post anaesthesia care unit
| Clinical | TOF group | P-value | |
| No. requiring airway maneuver, Yes/No | 38(45%),46(55%) | 12(14%),72(86%) | <0.0001 |
| Tactile stimulation, Yes/No | 18(21%), 66(79%) | 2(2%), 82(98%) | <0.0001 |
| Snoring, Yes/No | 26(31%),58(69%) | 10(12%),74(88%) | 0.003 |
| Respiratory rate | 16±2 | 17±3 | 0.0890 |
| Re-intubation, Yes/No | 0(0%), 84(100%) | 0(0%), 84(100%) | 0.36 |
shows logistic regression analysis for respiratory events in PACU
| Unadjusted odds | P-value | Adjusted odds ratio | P-value | |
| 0.023 | 0.11(0.14–0.93) | 0.043 | ||
| Study arm | 0.09(0.01–0.71) | 0.002 | 1.80(1.18–2.74) | 0.006 |
| Operative procedure | 1.90(1.25 –2.86) | 0.281 | ||
| Anesthetic duration | 1.00(1.01–1.01) | 0.548 | ||
| Duration since last muscle relaxant | 1.01(0.97–1.05) | |||
| BMI | 0.441 | |||
| 1.29(0.68–2.43) | ||||
| 0.002 | ||||
| Study arm | 0.09(0.02–0.40) | 0.205 | ||
| Operative procedure | 1.16(0.92–1.47) | 0.305 | ||
| Anesthetic duration | 1.00(0.997–1.01) | 0.797 | ||
| Duration since last muscle relaxant | 1.00(0.97–1.03) | |||
| BMI | 0.098 | |||
| 1.54(0.92–2.55) | ||||
| Study arm | <0.001 | |||
| Operative procedure | 0.20(0.10–0.43) | 0.107 | ||
| Anesthetic duration | 1.15(0.97–1.36) | 0.403 | ||
| Duration since last muscle relaxant | 1.00(0.997–1.01) | 0.420 | ||
| BMI | 1.00(0.97–1.01) | |||
| 0.104 | ||||
| 1.33(0.94–1.86) | ||||
| Study arm | 0.004 | |||
| Operative procedure | 0.30(0.13–0.68) | 0.717 | ||
| Anesthetic duration | 1.03(0.86–1.25) | 0.466 | ||
| Duration since last muscle relaxant | 1.00(1.00–1.01) | 0.918 | ||
| BMI | 1.00(0.98–1.02) | |||
| 0.119 | ||||
| 1.36(0.92–1.99) | ||||
-Smoking was not analyzed due to the very small numbers per group (4 each). Adjusted odds ratios were not calculated for tactile stimulation, airway manoeuvre and snoring because the other variables were not statistically significant.